Among our featured reports this week, we learn about how the vaginal microbiome may affect antiretroviral concentrations in the genital tract, and we look at the potential impact of global supply-chain interruptions on HIV drug resistance.
"When it comes to persistent low-level viremia in treated HIV patients, there's much agony, gnashing of teeth and confusion," Paul Sax, M.D. writes.
Among our four featured reports this week, we learn about the critical intersection between HIV treatment access and reduced HIV incidence in the U.S. -- and about the value of replacing placebos with PrEP in clinical trials on HIV prevention.
Among four noteworthy studies we highlight this week is a new addition to the vast mountain of evidence tying lung cancer risk to smoking -- but with an HIV-specific twist, and a caldera of hope for those who quit.
Among this week's collection of four study summaries are data indicating that reducing U.S. foreign aid for HIV-fighting efforts is a really bad idea, no matter which way you cut it.
This Week in HIV Research: Increased Muscle Area After Starting Treatment Likely Due to Fat Accumulation
This week, a study finds that increased muscle area after starting HIV treatment may be due to fat accumulation within the muscle rather than new muscle formation.
This week, a study finds that abstinence-only programs continue to be ineffective at keeping young people from having sex, and censor valuable information on HIV prevention.
This week, a study finds that the average time it takes to for newly diagnosed patients to enter care is three months.
We look at peroxisomes and neurocognitive impairment; injectable cabotegravir for PrEP; genital bacteria and HIV risk; and how HIV diagnosis relates to intimate partner violence among pregnant women.
This week, a study review finds that early interventions in monkeys, such as broadly neutralizing antibodies, can help lead to viral suppression without treatment.